• 1
    Rapport MM, Green AA, Page IH. Serum vasoconstrictor (serotonin). IV. Isolation and characterization. J. Biol. Chem. 1948; 176: 124351.
  • 2
    Nemecek GM, Coughlin SR, Handley DA, Moskowitz MD. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc. Natl Acad. Sci. USA 1986; 83: 6748.
  • 3
    Marcos E, Adnot S, Pham MH et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2003; 168: 48793.
  • 4
    Lee SL, Wang WW, Fanburg BL. Dexfenfluramine as a mitogen signal via the formation of superoxide anion. FASEB J. 2001; 15: 13245.
  • 5
    Eddahibi S, Fabre V, Boni C et al. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin. Circ. Res. 1999; 84: 32936.
  • 6
    Wanstall JC, Fiore SA, Gambino A, Chess-Williams R. Potentiation of 5-hydroxytryptamine (5-HT) responses by a 5-HT uptake inhibitor in pulmonary and systemic vessels: Effects of exposing rats to hypoxia. Naunyn Schmiedebergs Arch. Pharmacol. 2003; 368: 5207.
  • 7
    Eddahibi E, Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: Lessons for the future in pathogenesis. Respir. Res. 2002; 3: 912.
  • 8
    Eddahibi S, Hanoun N, Lanfumey L et al. Attenuated hypoxia pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. Invest. 2000; 105: 155562.
  • 9
    Maclean MR, Deuchar GA, Hicks MN et al. Overexpression of the 5-hydroxytryptamine transporter gene. Effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 2004; 109: 21505.
  • 10
    Eddahibi S, Chaouat A, Morrell N et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003; 108: 183944.
  • 11
    Morecroft I, Heeley RP, Prentice HM, Kirk A, Maclean MR. 5-Hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: Importance of the 5-HT1B receptor. Br. J. Pharmacol. 1999; 128: 7304.
  • 12
    Cooper JR, Bloom FE, Roth RH. Serotonin (5-hydroxytryptamine), histamine and adenosine. In: The Biochemical Basis of Neuropharmacology. Oxford University Press, New York. 2003; 271320.
  • 13
    Walther DJ, Bader MA. A unique central tryptophan hydroxylase isoform. Biochem. Pharmacol. 2003; 66: 167380.
  • 14
    Walther DJ, Peter JU, Bashammakh S et al. Synthesis of serotonin by a second trytophan hydroxylase isoform. Science 2003; 299: 76.
  • 15
    Vanhoutte PM. Platelet-derived serotonin, the endothelium, and cardiovascular disease. J. Cardiovasc. Pharmacol. 1991; 17 (Suppl. 5): S612.
  • 16
    Kawasaki H, Takasaki K. Enhanced 5-hydroxytryptamine release from vascular adrenergic nerves in spontaneously hypertensive rats. Hypertension 1987; 10: 3217.
  • 17
    Hoyer D, Clarke DE, Fozard JR et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 1994; 46: 158203.
  • 18
    Doggrell SA. The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation. Expert Opin. Invest. Drugs 2003; 12: 80523.
  • 19
    Watts SW. 5-HT in systemic hypertension: Foe, friend or fantasy? Clin. Sci. 2005; 108: 399412.
  • 20
    Tsukamoto K, Kurihara T, Nakayama N et al. Pressor responses to serotonin injected into the nucleus tractus solitarius of Sprague-Dawley rats and spontaneously hypertensive rats. Clin. Exp. Hypertens. 2000; 22: 6373.
  • 21
    Dalton DW. The cardiovascular effects of centrally administered 5-hydroxytryptamine in the conscious normotensive and hypertensive rat. J. Auton. Pharmacol. 1986; 6: 6775.
  • 22
    Slominski A, Pisarchik A, Semak I, Sweatman T, Szczesniewski A, Wortsman J. Serotoninergic system in hamster skin. J. Invest. Dermatol. 2002; 119: 93442.
  • 23
    Ikeda K, Tojo K, Otsubo C et al. 5-Hydroxytryptamine synthesis in HL-1 cells and neonatal rat cardiocytes. Biochem. Biophys. Res. Commun. 2005; 328: 5225.
  • 24
    Cote F, Fligny C, Fromes Y, Mallet J, Vodjdani G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol. Med. 2004; 10: 2328.
  • 25
    Matsumoto M, Yoshioka M, Togashi H, Tochihara M, Ikeda T, Saito H. Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis. J. Pharmacol. Exp. Ther. 1995; 272: 104451.
  • 26
    Saxena PR, Villalon CM. 5-Hydroxytryptamine: A chameleon in the heart. Trends Pharmacol. Sci. 1991; 12: 2237.
  • 27
    Nebigil CG, Maroteaux L. A novel role for serotonin in heart. Trends Cardiovasc. Med. 2001; 11: 32935.
  • 28
    Brattelid T, Qvigstad E, Lynham JA et al. Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failure. Naunyn Schmiedebergs Arch. Pharmacol. 2004; 370: 15766.
  • 29
    Stier CT, Itskovitz HD. Formation of serotonin by rat kidneys in vivo. Proc. Soc. Exp. Biol. Med. 1985; 180: 5507.
  • 30
    Moran A, Velasco C, Martin ML, San Roman L. Renal vasoconstrictor response to 5-hydroxytryptamine in the in situ autoperfused rat kidney: Involvement of angiotensin II and the 5-HT2 receptor activation. Eur. J. Pharmacol. 1997; 330: 20511.
  • 31
    Berndt TJ, Liang M, Tyce GM, Knox FG. Intrarenal serotonin, dopamine, and phosphate handling in remnant kidneys. Kidney Int. 2001; 59: 62530.
  • 32
    Delarue C, Leboulenger F, Morra M et al. Immunohistochemical and biochemical evidence for the presence of serotonin in amphibian adrenal chromaffin cells. Brain Res. 1988; 459: 1726.
  • 33
    Verhofstad AA, Jonsson G. Immunohistochemical and neurochemical evidence for the presence of serotonin in the adrenal medulla of the rat. Neuroscience 1983; 10: 144353.
  • 34
    Fernandez-Vivero J, Rodriguez-Sanchez F, Verastegui C, Cordoba Moriano F, Romero A, De Castro JM. Immunocytochemical distribution of serotonin and neuropeptide Y (NPY) in mouse adrenal gland. Histol. Histopathol. 1993; 8: 50920.
  • 35
    Delarue C, Becquet D, Idres S, Hery F, Vaudry H. Serotonin synthesis in adrenochromaffin cells. Neuroscience 1992; 46: 495500.
  • 36
    Orso E, Szalay KS, Toth IE et al. Effect of histamine on corticosteroid secretion of isolated human and rat adrenocortical cells. Inflamm. Res. 1995; 44: S489.
  • 37
    Hinson JP, Vinson GP, Pudney J, Whitehouse BJ. Adrenal mast cells modulate vascular and secretory responses in the intact adrenal gland of the rat. J. Endocrinol. 1989; 121: 25360.
  • 38
    Lefebvre H, Compagnon P, Contesse V et al. Production and metabolism of serotonin (5-HT) by the human adrenal cortex: Paracrine stimulation of aldosterone secretion by 5-HT. J. Clin. Endocrinol. Metab. 2001; 86: 50017.
  • 39
    Lefebvre H, Contesse V, Delarue C et al. Effect of the serotonin-4 receptor agonist zacopride on aldosterone secretion from the human adrenal cortex: In vivo and in vitro studies. J. Clin. Endocrinol. Metab. 1993; 77: 16626.
  • 40
    Rocco S, Ambroz C, Aguilera G. Interaction between serotonin and other regulators of aldosterone secretion in rat adrenal glomerulosa cells. Endocrinology 1990; 127: 310310.
  • 41
    Lefebvre H, Contesse V, Delarue C et al. The serotonin-4 receptor agonist cisapride and angiotensin-II exert additive effects on aldosterone secretion in normal man. J. Clin. Endocrinol. Metab. 1995; 80: 5047.
  • 42
    Lefebvre H, Gonzalez KN, Contesse V, Delarue C, Vaudry H, Kuhn JM. Effect of prolonged administration of the serotonin4 (5-HT4) receptor agonist cisapride on aldosterone secretion in healthy volunteers. Endocr. Res. 1998; 24: 74952.
  • 43
    Sugimoto Y, Yamada J, Yoshikawa T, Nishikaw F, Noma T, Horisaka K. The involvement of serotonin in the catecholamine release from the adrenal medulla. Adv. Exp. Med. Biol. 1996; 398: 5613.
  • 44
    Yildiz O, Smith JR, Purdy RE. Serotonin and vasoconstrictor synergism. Life Sci. 1998; 62: 172332.
  • 45
    Watts SW. 5-Hydroxytryptamine-induced potentiation of endothelin-1- and norepinephrine-induced contraction is mitogen-activated protein kinase pathway dependent. Hypertension 2000; 35: 2448.
  • 46
    Martin GR. Vascular receptors for 5-hydroxytryptamine: Distribution, function and classification. Pharmacol. Ther. 1994; 62: 283324.
  • 47
    McDuffie JE, Motley ED, Limbird LE, Maleque MA. 5-Hydroxytryptamine stimulates phosphorylation of p44/p42 mitogen-activated protein kinase activation in bovine aortic endothelial cell cultures. J. Cardiovasc. Pharmacol. 2000; 35: 398402.
  • 48
    Hoffman BJ, Mezey E, Brownstein MJ. Cloning of a serotonin transporter affected by antidepressants. Science 1991; 254: 57980.
  • 49
    Blakely RD, Berson HE, Fremeau RT et al. Cloning and expression of a functional serotonin transporter from rat brain. Nature 1991; 354: 6670.
  • 50
    Ramamoorthy S, Bauman AL, Moore KR et al. Antidepressant and cocaine-sensitive human serotonin transporter: Molecular cloning, expression and chromosomal localization. Proc. Natl Acad. Sci. USA 1993; 90: 25426.
  • 51
    Chang AS, Chang SM, Starnes DM, Schroeter S, Bauman AL, Blakely RD. Cloning and expression of the mouse serotonin transporter. Brain Res. Mol. Brain Res. 1996; 43: 18592.
  • 52
    Chen NH, Reith MEA. Structure–function relationships for biogenic amine neurotransmitter transporters. In: ReithMEA (ed.). Contemporary Neuroscience: Neurotransmitter Transporters, Functional and Regulation, 2nd edn. Humana Press, Totowa. 2002; 53109.
  • 53
    Ramammoorthy S. Regulation of monoamine transporters: Regulated phosphorylation, dephosphorylation and trafficking. In: ReithMEA (ed.). Contemporary Neuroscience: Neurotransmitter Transporters, Functional and Regulation, 2nd edn. Humana Press, Totowa. 2002; 123.
  • 54
    Kilic F, Rudnick G. Oligomerization of the serotonin transporter and its functional consequences. Proc. Natl Acad. Sci. USA 2000; 97: 310611.
  • 55
    Schmid JA, Just H, Sitte HH. Impact of oligomerization on the function of the human serotonin receptor. Biochem. Soc. Trans. 2001; 29: 7326.
  • 56
    Ozaslan D, Wang S, Ahmed BA et al. Glycosyl modification facilitates homo- and hetero-oligomerization of the serotonin transporter. A specific role for sialic acid residues. J. Biol. Chem. 2003; 278: 43 991–4000.
  • 57
    Kocabas AM, Rudnick G, Kilic F. Functional consequences of homo- but not hetero-oligomerization between transporters for the biogenic amine neurotransmitters. J. Neurochem. 2003; 85: 151320.
  • 58
    Schmid JA, Scholze P, Kudlacek O, Freissmuth M, Singer EA, Sitte HH. Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells. J. Biol. Chem. 2001; 276: 380510.
  • 59
    Galli A, Petersen CI, DeBlaquiere M, Blakely RD, De Felice LJ. Drosophila serotonin transporters have voltage-dependent uptake coupled to a serotonin gated channel. J. Neurosci. 1997; 17: 340111.
  • 60
    Walther DJ, Peter JU, Winter S et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet α-granule release. Cell 2003; 115: 85162.
  • 61
    Griffin M, Casadio R, Bergamini CM. Transglutaminases: Nature's biological glues. Biochem. J. 2002; 368: 37796.
  • 62
    Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, chlorphentermine are serotonin transporter substrates; implications for primary pulmonary hypertension. Circulation 1999; 100: 86975.
  • 63
    Abenhaim L, Moride Y, Brenot F et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N. Engl. J. Med. 1996; 355: 60916.
  • 64
    Connolly HM, Crary JL, Mcgood MD et al. Valvular heart disease associated with fenfluramine–phentermine. N. Engl. J. Med. 1997; 337: 5818.
  • 65
    Rudnick G, Wall SC. The molecular mechanism of ‘ecstasy’[3,4-methylenedioxy-methamphetamine (MDMA)]: Serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl Acad. Sci. USA 1992; 89: 181721.
  • 66
    Mlinar B, Corradetti R. Endogenous 5-HT, released by MDMA through serotonin transporter- and secretory vesicle-dependent mechanisms, reduces hippocampal excitatory synaptic transmission by preferential activation of 5-HT1B receptors located on CA1 pyramidal neurons. Eur. J. Neurosci. 2003; 18: 155971.
  • 67
    Ramamoorthy S, Giovanetti E, Qian Y, Blakely RD. Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. J. Biol. Chem. 1998; 273: 245866.
  • 68
    Blakely RD, Ramamoorthy S, Schroeter S et al. Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol. Psychiatry 1998; 44: 16978.
  • 69
    Samuvel DJ, Jayanthi LD, Bhat NR, Ramamoorthy S. A role for p38 mitogen-activated protein kinase in the regulation of the serotonin transporter: Evidence for distinct cellular mechanisms involved in transporter surface expression. J. Neurosci. 2005; 25: 2941.
  • 70
    Heils A, Teufel A, Petri S et al. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 1996; 66: 26214.
  • 71
    Murphy DL, Lerner A, Rudnick G, Lesch KP. Serotonin transporter: Gene, genetic disorders, and pharmacogenetics. Mol. Interv. 2004; 4: 10923.
  • 72
    Mortensen OV, Kristensen AS, Rudnick G, Wiborg O. Molecular cloning, expression and characterization of a bovine serotonin transporter. Mol. Brain Res. 1999; 71: 1206.
  • 73
    Ni W, Thompson J, Northcott C, Lookingland K, Watts SW. The serotonin transporter is present and functional in peripheral arterial smooth muscle. J. Cardiovasc. Pharmacol. 2004; 43: 77081.
  • 74
    Huang J, Pickel VM. Serotonin transporters (SERTs) within the rat nucleus of the solitary tract: Subcellular distribution and relation to 5-HT2A receptors. J. Neurocytol. 2002; 31: 66779.
  • 75
    Schroeter S, Levey AL, Blakely RD. Polarized expression of antidepressant sensitive serotonin transporter in epinephrine-synthesizing chromaffin cells of the rat adrenal gland. Mol. Cell. Neurosci. 1997; 9: 17084.
  • 76
    Armando I, Tjurmina OA, Li Q, Murphy DL, Saavedra JM. The serotonin transporter is required for stress-evoked increases in adrenal catecholamine synthesis and angiotensin II AT(2) receptor expression. Neuroendocrinology 2003; 78: 21725.
  • 77
    Morecroft I, Loughlin L, Nilsen M et al. Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J. Pharmacol. Exp. Ther. 2005; 313: 53948.
  • 78
    Gonzalez AM, Smith AP, Emery CJ, Higenbottam TW. The pulmonary hypertensive fawn-hooded rat has a normal serotonin transporter coding sequence. Am. J. Respir. Cell Mol. Biol. 1998; 19: 2459.
  • 79
    Wanstall JC, Fiore SA, Gambino A, Chess-Williams R. Potentiation of 5-hydroxytryptamine (5-HT) responses by a 5-HT uptake inhibitor in pulmonary and systemic vessels: Effects of exposing rats to hypoxia. Naunyn Schmiedebergs Arch. Pharmacol. 2003; 368: 5207.
  • 80
    Weir EK, Reeve HL, Huang JM et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstrction. Circulation 1996; 94: 221620.
  • 81
    Desta B, Steed S, Ravel D, Laudignon N, Vanhoutte PM, Boulanger CM. Acute and chronic effects of dexfenfluramine on the porcine pulmonary artery. Gen. Pharmacol. 1998; 30: 40310.
  • 82
    Barman SA, Isales CM. Fenfluramine potentiates canine pulmonary vasoreactivity to endothelin-1. Pulm. Pharmacol. Ther. 1999; 11: 1837.
  • 83
    Hong Z, Olschewski A, Reeve HL, Nelson DP, Hong F, Weir EK. Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am. J. Physiol. Lung Cell Mol. Physiol. 2004; 286: L5318.
  • 84
    Greenberg BD, Tolliver TJ, Huang S-J, Li Q, Bengel D, Murphy DL. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am. J. Med. Genet. 1999; 88: 837.
  • 85
    Bengel D, Murphy DL, Andrews AM et al. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine (‘ecstasy’) in serotonin transporter deficient mice. Mol. Pharmacol. 1998; 53: 64955.
  • 86
    Maurer-Spurej E. Serotonin reuptake inhibitors and cardiovascular disease: A platelet connection. Cell Mol. Life Sci. 2005; 62: 15970.
  • 87
    Kurne E, Ertugrul A, Anil Yagcioglu AE, Yazici KM. Venous thromobembolism and escilatolopram. Gen. Hosp. Psychiatry 2004; 26: 4813.
  • 88
    Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J. Toxicol. Clin. Toxicol. 2004; 42: 27785.
  • 89
    Degner D, Grohmann R, Kropp S et al. Severe adverse drug reactions of antidepressants: Results of the German multicenter drug surveillance program MSP. Pharmacopsychiatry 2004; 37 (Suppl. 1): S3945.
  • 90
    Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin. Pharmacol. Ther. 2004; 75: 23441.
  • 91
    Khawaja IS, Feinstein RE. Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants. Heart Dis. 2003; 5: 15360.
  • 92
    Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: Association with use of tricyclic agents. Am. J. Med. 2000; 108: 28.
  • 93
    Settle EC. Antidepressant drugs: Disturbing and potentially dangerous adverse effects. J. Clin. Psychiatry 1998; 59: 2530.
  • 94
    Kelly CA, Dhaun N, Laing WJ, Strachan FE, Good AM, Bateman DN. Comparative toxicity of citalopram and the newer antidepressants after overdose. J. Toxicol. Clin. Toxicol. 2004; 42: 6771.
  • 95
    Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: New drugs, old concerns? Curr. Pharm. Des. 2004; 10: 246375.
  • 96
    Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr. Med. Chem. 1999; 6: 46980.
  • 97
    Pacher P, Ungvari Z, Kecskemeti V, Furst S. Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants. Curr. Med. Chem. 1998; 5: 38190.
  • 98
    Tomita T, Umegaki K, Hayashi E. Hypoaggregability of washed platelets from stroke-prone spontaneously hypertensive rats (SHRSP). Stroke 1984; 15: 705.
  • 99
    Umegaki K, Ichikawa T. Vitamin E did not prevent platelet activation, but prevented increase of lipid peroxides and renal dysfunction in DOCA-salt hypertensive rats. J. Nutr. Sci. Vitaminol. 1993; 39: 43749.
  • 100
    Ding YA, Chou TC, Huan R. Are platelet cytosolic free calcium, serotonin concentration and blood viscosity different between hypertensive and normotensive subjects? Cardiology 1994; 85: 7681.
  • 101
    Kamal LA, Le Quan-Bui KH, Meyer P. Decreased uptake of 3H-serotonin and endogenous content of serotonin in blood platelets in hypertensive patients. Hypertension 1984; 6: 56873.
  • 102
    Lazartigues E, Brefel-Courbon C, Bagheri H et al. Fluoxetine-induced pressor response in freely moving rats: A role for vasopressin and sympathetic tone. Fundam. Clin. Pharmacol. 2000; 14: 44351.
  • 103
    Amsterdam JD, Garcia-Espana F, Fawcett J et al. Blood pressure changes during short term fluoxetine. J. Clin. Psychopharmacol. 1999; 19: 914.
  • 104
    Tsai ML, Lin MT. Hypertension and tachycardia produced by inhibition of reuptake of 5-hydroxytryptamine by fluoxetine in the rat. Neuropharmacology 1986; 25: 799802.
  • 105
    Grubb BP, Samoil D, Kosinski D, Wolfe D, Lorton M, Madu E. Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension. Am. J. Med. 1994; 97: 3668.
  • 106
    Bergeron L, Boule M, Perreault S. Serotonin toxicity associated with concomitant use of linezolid. Ann. Pharmacother. 2005; 39: 95661.
  • 107
    Skop BF, Finkelstein JA, Mareth TR, Magoon MR, Brown TM. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am. J. Emerg. Med. 1994; 12: 6424.
  • 108
    Mason P, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine 2000; 79: 2019.
  • 109
    Dalfen AK, Stewart DE. Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors? Can. J. Psychiatry 2001; 46: 25863.
  • 110
    Wassertheil-Smoller S, Shumaker S, Ockene J et al. Depression and cardiovascular sequela in postmenopausal women: The Women's Health Initiative (WHI). Arch. Intern. Med. 2004; 164: 28998.
  • 111
    Hoefgen B, Schulze TG, Ohlraun S et al. The power of sample size and homogenous sampling: Association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol. Psychiatry 2005; 57: 24751.
  • 112
    Plante GE. Depression and cardiovascular disease: A reciprocal relationship. Metabolism 2005; 54: 458.
  • 113
    Cohen HW, Madhavan S, Alderman MH. History of treatment for depression: Risk factor for myocardial infarction in hypertensive patients. Psychosom. Med. 2001; 63: 2039.
  • 114
    Rafanelli C, Roncuzzi R, Milaneschi Y et al. Stressful life events, depression and demoralization as risk factors for acute coronary heart disease. Psychother. Psychosom. 2005; 74: 17984.
  • 115
    Fumeron F, Betoulle D, Nicaud V et al. Serotonin transporter gene polymorphism and myocardial infarction: Etude Cas-Temoins de I’Infarctus du Myocarde (ECTIM). Circulation 2002; 105: 29435.
  • 116
    Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003; 108: 326.
  • 117
    Schlienger RG, Meier CR. Effect of selective serotonin reuptake inhibitors on platelet activation: Can they prevent acute myocardial infarction? Am. J. Cardiovasc. Drugs 2003; 3: 14962.
  • 118
    Paczkowski FA, Bryan-Lluka LJ, Porzgen P, Bruss M, Bonish H. Comparison of the pharmacological properties of cloned rat, human and bovine norepinephrine transporters. J. Pharmacol. Exp. Ther. 1999; 290: 7617.
  • 119
    Chen JJ, Li Z, Pan H et al. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high affinity serotonin transporter: Abnormal intestinal motility and the expression of cation transporters. J. Neurosci. 2001; 21: 634861.
  • 120
    Martel F, Azevedo I. An update on the extraneuronal monoamine transporter (EMT) characteristics, distribution and regulation. Curr. Drug Metab. 2003; 4: 31318.
  • 121
    Horvath G, Sutto Z, Torbati A, Conner GE, Salathe M, Wanner A. Norepinephrine transport by the extraneuronal monoamine transporter in human bronchial arterial smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2003; 285: L82937.